STOCKHOLM, Nov. 7, 2018 /PRNewswire/ -- Immunovia's IMMray™
platform for blood-based biomarker signatures offers exciting new
opportunities to develop accurate diagnostic tests that can detect
diseases at an early stage. During the period we presented new
results and identified no fewer than two new areas for strategic
focus in our ongoing development activities – non-small cell lung
cancer and Rheumatoid Arthritis (RA).
In August we presented the results from our first collaboration
trial with a global, top-ten pharmaceutical business. The results
showed that Immunovia's blood-based IMMray™ biomarker array
produced very high accuracy in the diagnosis of non-small cell lung
cancer. Later in August we presented the results from the latest of
three completed studies within autoimmune testing. The studies
represented a breakthrough, showing that IMMray™ can also have
significance in the diagnosis of autoimmune rheumatoid diseases. As
a consequence of the trial's exceptionally good results, we have
decided to make Rheumatoid Arthritis (RA) a strategic focus area
within autoimmunity.
These results for new applications clearly indicate the broad
usability of the IMMray™ platform for addressing a large amount of
unsolved problems within the fields of cancer, autoimmunity and
other complex diseases. This means there is an opening for IMMray™
becoming a significant platform in global diagnostics for the
future.
As reported at the start of the quarter, new data has emerged
showing that optimization of IMMray™ PanCan –d is required before
the product can be launched on the market. This means a delay in
the sales start until the latter part of 2019. Work on IMMray™
PanCan –d has continued during the quarter with undiminished
intensity in the face of these new circumstances.
Immunovia's financial targets were updated before the previous
interim report and remain in place.
- Mats Grahn, CEO of Immunovia
AB
Key indicatiors
Key indicators
(SEK thousand unless otherwise stated)
|
1 July–30 Sept.
2018
|
1 July–30 Sept.
2017
|
1 Jan.-30 Sept.
2018
|
1 Jan.-30 Sept.
2017
|
Full year
2017
|
Net sales
|
85
|
27
|
241
|
122
|
149
|
Operating
earnings
|
– 17,344
|
– 11,641
|
– 61,952
|
– 30,157
|
– 45,520
|
Earnings before
tax
|
– 17,403
|
– 11,589
|
– 60,876
|
– 29,914
|
– 45,232
|
Net
earnings
|
– 17,403
|
– 11,589
|
– 60,883
|
– 29,914
|
– 45,232
|
Earnings per share
before and after dilution (SEK/share)
|
– 0.89
|
– 0.69
|
– 3.34
|
– 1.78
|
– 2.67
|
Equity ratio,
%
|
97
|
97
|
97
|
97
|
94
|
No. of shares at the
end of the period
|
19,531,353
|
17,318,059
|
19,531,353
|
17,318,059
|
17,318,059
|
Average no. of shares
before and after dilution
|
19,487,025
|
16,804,059
|
18,212,275
|
16,804,059
|
16,932,559
|
This financial statement has been produced in accordance with
IFRS for the Immunovia Group, which comprises Immunovia AB and the
wholly-owned subsidiaries, Immunovia Inc and Immunovia
GmbH.
Outlook
Immunovia is focused on fundamentally transforming diagnosis of
complex forms of cancer and autoimmune diseases. The antibody-based
platform, IMMray™, is the result of 15 years of research at CREATE
Health – the Center for Translational Cancer Research at
Lund University, Sweden. IMMray™ is a technology platform for
the development of diagnostic tests and the company's primary test,
IMMray™ PanCan –d, is the first test in the world for early
diagnosis of pancreatic cancer.
The company's financial targets remain in place from the
previous quarter. The company expects to receive the first revenues
from self-pay sales in the latter part of 2019. The following
financial targets have been established:
• Immunovia's target is to achieve turnover of SEK 250-300 million by 2022 based on self-pay for
IMMray™ PanCan –d.
• Immunovia's target is to achieve total turnover, including
payment via self-pay and cost remuneration from insurance systems,
of SEK 800-1,000 million by 2024.
For more information, please contact:
Mats Grahn
Chief Executive Officer, CEO, Immunovia
Tel.: +46-70-5320230
Email: mats.grahn@immunovia.com
About Immunovia
Immunovia AB was founded in 2007 by investigators from the
Department of Immunotechnology at Lund University and CREATE Health, the Center
for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to
decipher the wealth of information in blood and translate it into
clinically useful tools to diagnose complex diseases such as
cancer, earlier and more accurately than previously possible.
Immunovia´s core technology platform, IMMray™, is based on antibody
biomarker microarray analysis. The company is now performing
clinical validation studies for the commercialization of IMMray™
PanCan-d that could be the first blood based test for early
diagnosis of pancreatic cancer. In the beginning of 2016, the
company started a program focused on autoimmune diseases
diagnosis, prognosis and therapy monitoring.
(Source: www.immunovia.com)
This information is information that Immunovia AB is obliged to
make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication, through the agency of
the contact person set out above.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/immunovia-ab/r/immunovia-interim-report-january-september-2018,c2665825
The following files are available for download:
http://mb.cision.com/Main/13121/2665825/940225.pdf
|
Immunovia Q3 2018
Eng
|
View original
content:http://www.prnewswire.com/news-releases/immunovia-interim-report-january-september-2018-300745470.html
SOURCE Immunovia AB